A Phase 1/2 interventional study of BMS-986016 and BMS-936558 in Hematologic Neoplasms, sponsored by Bristol-Myers Squibb. Completed at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-24.
Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Hematologic Neoplasms by Bristol-Myers Squibb — none open to participants now, none under way, none of them phase 3. Hematologic Neoplasms · Bristol-Myers Squibb.
Among the 16 studies in Hematologic Neoplasms by Bristol-Myers Squibb, this one is the 3rd largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2014, is one of 3 in phase 1/2, and was the 11th registered.
1,445 studies on the registry are indexed under Hematologic Neoplasms; 421 are open to participants now.
Browse Hematologic Neoplasms studies →None of the 16 studies in Hematologic Neoplasms by Bristol-Myers Squibb is open now. The open studies under Hematologic Neoplasms, anywhere →
Of the 314 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 7 · Phase 3 1
First in 2007; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 106 is above the median of 46 across 1,044 interventional studies indexed under Hematologic Neoplasms.
Median enrollment 60 across the 13 interventional studies, 117 across the 3 observational. Of the 15 that completed or were terminated, 7 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Hematologic Neoplasms by Bristol-Myers Squibb, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to characterize the safety, tolerability, dose-limiting toxicities (DLTs), and maximum tolerated dose (MTD) of relatlimab administered alone or in combination with nivolumab to subjects with relapsed or refractory B-cell malignancies. Co-primary objective is to investigate the preliminary efficacy of relatlimab in combination with nivolumab in subjects with relapsed or refractory Hodgkin lymphoma (HL), and relapsed or refractory Diffused Large B Cell lymphoma (DLBCL)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: BMS-986016
Biological: BMS-986016 · Biological: BMS-936558
Biological: BMS-986016
Biological: BMS-986016 · Biological: BMS-936558
Specified Dose on Specified Days
Also known as: Anti-LAG-3 (Anti-Lymphocyte Activation Gene-3), relatlimab
Specified Dose on Specified Days
Also known as: Anti-PD-1 (Anti-Programmed-Death-1), MDX-1106, nivolumab
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation
Number of participants with any grade adverse events (AEs), any grade serious adverse events (SAEs) and any grade AEs leading to discontinuation of any drug. The severity of AEs will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0. An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
Time frame: From first dose to 100 days post last dose (Up to 51 months)
Number of Participants Who Died
Number of participants who died due to any cause.
Time frame: From first dose to 135 days post last dose (Up to 52 months)
Number of Participants With On-Treatment Laboratory Abnormalities in Specific Hepatics Tests
Number of participants with laboratory abnormalities in specific hepatic tests based on SI unit convention. The number of participants with the following laboratory abnormalities from on-treatment evaluations will be summarized: * ALT or AST \> 3 x ULN, \> 5 x ULN, \> 10 x ULN and \> 20 x ULN * Total bilirubin \> 2 x ULN * ALP \> 1.5 x ULN * Concurrent (within 1 day) ALT or AST \> 3 x ULN and total bilirubin \> 1.5 x ULN * Concurrent (within 30 days) ALT or AST \> 3 x ULN and total bilirubin \> 1.5 x ULN * Concurrent (within 1 day) ALT or AST \> 3 x ULN and total bilirubin \> 2 x ULN * Concurrent (within 30 days) ALT or AST \> 3 x ULN and total bilirubin \> 2 x ULN
Time frame: From first dose to 30 days post last dose (Up to 49 months)
Objective Response Rate (ORR) - Part D
Investigator-assessed ORR per International Working Group (IWG 2007) response criteria for malignant lymphoma is defined as the number of participants with a best overall documented response (BOR) of either a complete response (CR) or partial response (PR). Complete response: Disappearance of all evidence of disease. Partial response: Regression of measurable disease and no new sites. \>= 50% decrease in sum of the produce of the diameters of up to 6 largest dominant masses (index lesions); no increase in size of other nodes (non-index lesions). Progressive disease: Any new lesion or increase by \>=50% of previously involved sites from nadir.
Time frame: From first dose date to the date of disease progression per investigator or the date of subsequent therapy, whichever occurs first (Up to approximately 95 months)
Duration of Response (DoR) - Part D
Investigator-assessed DoR per International Working Group (IWG 2007)) response criteria for malignant lymphoma is defined as the time between the date of first documented response (complete response or partial response) to the date of the first objectively documented progression, or death due to any cause, whichever occurs first. Complete response: Disappearance of all evidence of disease. Partial response: Regression of measurable disease and no new sites. \>= 50% decrease in sum of the produce of the diameters of up to 6 largest dominant masses (index lesions); no increase in size of other nodes (non-index lesions). Progressive disease: Any new lesion or increase by \>=50% of previously involved sites from nadir.
Time frame: From first dose to the date of the first objectively documented progression, or death due to any cause, whichever occurs first (Up to approximately 95 months)
BMS-986016 Maximum Observed Serum Concentration (Cmax)
BMS-986016 Maximum Observed Serum Concentration (Cmax). Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 = Re-challenge period
Time frame: PK assessment include the following timepoints: pre-dose, 1, 4, 24, 48, 96, 144, 192 hours end-of-infusion on cycle 1 Day 1, Cycle 3 Day 1
BMS-986016 Time of Maximum Observed Serum Concentration (Tmax)
BMS-986016 Time of Maximum Observed Serum Concentration (Tmax). Period 0 = treatment period Period 1 = Re-challenge period
Time frame: PK assessment include the following timepoints: pre-dose, 1, 4, 24, 48, 96, 144, 192 hours end-of-infusion on cycle 1 Day 1, Cycle 3 Day 1
BMS-986016 Area Under the Concentration-time Curve in One Dosing Interval (AUC(TAU))
BMS-986016 Area under the concentration-time curve in one dosing interval (AUC(TAU)). Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 = Re-challenge period
Time frame: PK assessment include the following timepoints: pre-dose, 1, 4, 24, 48, 96, 144, 192 hours end-of-infusion on cycle 1 Day 1, Cycle 3 Day 1
BMS-986016 Concentration at the End of a Dosing Interval (Ctau)
BMS-986016 Concentration at the end of a dosing interval (Ctau). Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 = Re-challenge period
Time frame: PK assessment include the following timepoints: pre-dose, 1, 4, 24, 48, 96, 144, 192 hours end-of-infusion on cycle 1 Day 1, Cycle 3 Day 1
BMS-986016 Effective Elimination Half-life That Explains the Degree of AUC Accumulation Observed (T 1/2eff AUC)
BMS-986016 effective elimination half-life that explains the degree of AUC accumulation observed (t 1/2eff AUC). Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 = Re-challenge period
Time frame: PK assessment include the following timepoints: pre-dose, 1, 4, 24, 48, 96, 144, 192 hours end-of-infusion on cycle 1 Day 1, Cycle 3 Day 1
BMS-986016 Total Body Clearance (CL/T)
BMS-986016 total body clearance (CL/T). Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 = Re-challenge period
Time frame: PK assessment include the following timepoints: pre-dose, 1, 4, 24, 48, 96, 144, 192 hours end-of-infusion on cycle 1 Day 1, Cycle 3 Day 1
BMS-986016 Cmax Accumulation Index (AI_Cmax)
BMS-986016 cmax accumulation index (AI_Cmax). AI is calculated based on ratio of Cmax at steady state to Cmax after the first dose. Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 - Re-challenge period
Time frame: PK assessment include the following timepoints: pre-dose, 1, 4, 24, 48, 96, 144, 192 hours end-of-infusion on cycle 1 Day 1, Cycle 3 Day 1
BMS-986016 Accumulation Index (AI_AUC)
BMS-986016 accumulation index (AI_AUC). AI is calculated based on ratio of AUC(TAU) at steady state to AUC(TAU) after the first dose. Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 - Re-challenge period
Time frame: PK assessment include the following timepoints: pre-dose, 1, 4, 24, 48, 96, 144, 192 hours end-of-infusion on cycle 1 Day 1, Cycle 3 Day 1
BMS-986016 Ctau Accumulation Index (AI_Ctau)
BMS-986016 Ctau accumulation index (AI_Ctau). AI is calculated based on ratio of Ctau at steady state to Ctau after the first dose. Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 - Re-challenge period
Time frame: PK assessment include the following timepoints: pre-dose, 1, 4, 24, 48, 96, 144, 192 hours end-of-infusion on cycle 1 Day 1, Cycle 3 Day 1
BMS-986016 Average Concentration Over a Dosing Interval ([AUC(TAU)/Tau] (Css,Avg)
BMS-986016 average concentration over a dosing interval (\[AUC(TAU)/tau\] (Css,avg). Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 - Re-challenge period
Time frame: PK assessment include the following timepoints: pre-dose, 1, 4, 24, 48, 96, 144, 192 hours end-of-infusion on cycle 1 Day 1, Cycle 3 Day 1
BMS-986016 Trough Observed Serum Concentration (Ctrough)
BMS-986016 trough observed serum concentration (Ctrough). Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 - Re-challenge period
Time frame: PK assessment include the following timepoints: pre-dose, 1, 4, 24, 48, 96, 144, 192 hours end-of-infusion on cycle 1 Day 15, 29, 43, Cycle 2 Day 1, 15, 29, Cycle 3 Day 1, 15, Cycle 5 Day 1, Cycle 7 Day 1, Cycle 9 Day 1, and Cycle 11 Day 1
Number of Participants With Anti-BMS-986016 Antibodies (ADA)
Number of participants with anti-BMS-986016 antibodies (ADA) with status as baseline ADA positive, ADA positive and ADA negative. Baseline ADA positive participant is defined as a participant with positive seroconversion detected in the last sample before initiation of treatment. ADA-positive participant is a participant with at least one ADA-positive sample relative to baseline after initiation of the treatment. ADA negative participant is defined as a participant with no ADA positive sample after the initiation of treatment.
Time frame: From first dose to 135 days post last dose (Up to 52 months)
Number of Participants With Anti-Nivolumab Antibodies (ADA)
Number of participants with anti-Nivolumab antibodies (ADA) with status as baseline ADA positive, ADA positive and ADA negative. Baseline ADA positive participant is defined as a participant with positive seroconversion detected in the last sample before initiation of treatment. ADA-positive participant is a participant with at least one ADA-positive sample relative to baseline after initiation of the treatment. ADA negative participant is defined as a participant with no ADA positive sample after the initiation of treatment.
Time frame: From first dose to 135 days post last dose (Up to 52 months)
| Milestone | BMS-986016 20mg | BMS-986016 80mg | BMS-986016 800mg | BMS-986016 240mg | BMS-986016 240mg Part B | BMS-986016 80mg + Nivolumab | BMS-986016 240mg + Nivolumab | BMS-986016 160mg + Nivolumab | BMS-986016 160mg + Nivolumab Part D |
|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 9 | 6 | 9 | 11 | 7 | 1 | 4 | 56 |
| Chronic lymphocytic leukemia (cll) | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Diffuse large b-cell lymphoma (dlbcl) | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 15 |
| Indolent non-hodgkin lymphoma (inhl) | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 |
| Hodgkin lymphoma (hl) | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 |
| Hl-anti-pd-1 naive | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 21 |
| Hl-anti-pd-1 progressed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20 |
| Completed | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 5 |
| Not completed | 3 | 8 | 6 | 9 | 11 | 5 | 1 | 4 | 51 |
| Withdrew: Disease progression | 2 | 8 | 4 | 5 | 9 | 3 | 1 | 2 | 28 |
| Withdrew: Study drug toxicity | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 6 |
| Withdrew: Adverse event unrelated to study drug | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Participant request to discontinue study treatment | 0 | 0 | 2 | 2 | 0 | 1 | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Maximum clinical benefit | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 6 |
| Withdrew: Participant no longer meets study criteria | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Other reasons | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 6 |
Number of participants with any grade adverse events (AEs), any grade serious adverse events (SAEs) and any grade AEs leading to discontinuation of any drug. The severity of AEs will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0. An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
| Participants | BMS-986016 20mg | BMS-986016 80mg | BMS-986016 800mg | BMS-986016 240mg | BMS-986016 80mg + Nivolumab | BMS-986016 240mg + Nivolumab | BMS-986016 160mg + Nivolumab |
|---|---|---|---|---|---|---|---|
| AEs | 3 | 9 | 5 | 19 | 7 | 1 | 59 |
| SAEs | 1 | 4 | 2 | 6 | 4 | 0 | 26 |
| AEs leading to discontinuation | 1 | 2 | 0 | 1 | 1 | 0 | 9 |
Number of participants who died due to any cause.
| Participants | BMS-986016 20mg | BMS-986016 80mg | BMS-986016 800mg | BMS-986016 240mg | BMS-986016 80mg + Nivolumab | BMS-986016 240mg + Nivolumab | BMS-986016 160mg + Nivolumab |
|---|---|---|---|---|---|---|---|
| Number of Participants Who Died | 0 | 2 | 1 | 2 | 2 | 0 | 10 |
Number of participants with laboratory abnormalities in specific hepatic tests based on SI unit convention. The number of participants with the following laboratory abnormalities from on-treatment evaluations will be summarized: * ALT or AST \> 3 x ULN, \> 5 x ULN, \> 10 x ULN and \> 20 x ULN * Total bilirubin \> 2 x ULN * ALP \> 1.5 x ULN * Concurrent (within 1 day) ALT or AST \> 3 x ULN and total bilirubin \> 1.5 x ULN * Concurrent (within 30 days) ALT or AST \> 3 x ULN and total bilirubin \> 1.5 x ULN * Concurrent (within 1 day) ALT or AST \> 3 x ULN and total bilirubin \> 2 x ULN * Concurrent (within 30 days) ALT or AST \> 3 x ULN and total bilirubin \> 2 x ULN
| Participants | BMS-986016 20mg | BMS-986016 80mg | BMS-986016 800mg | BMS-986016 240mg | BMS-986016 80mg + Nivolumab | BMS-986016 240mg + Nivolumab | BMS-986016 160mg + Nivolumab |
|---|---|---|---|---|---|---|---|
| ALT OR AST > 3XULN | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| ALT OR AST > 5XULN | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| ALT OR AST > 10XULN | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| ALT OR AST > 20XULN | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| TOTAL BILIRUBIN > 2XULN | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| ALP > 1.5XULN | 1 | 1 | 0 | 1 | 1 | 0 | 8 |
| CONCURRENT ALT OR AST ELEVATION > 3XULN WITH TOTAL BILIRUBIN > 1.5XULN WITHIN ONE DAY | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| CONCURRENT ALT OR AST ELEVATION > 3XULN WITH TOTAL BILIRUBIN > 1.5XULN WITHIN 30 DAYS | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| CONCURRENT ALT OR AST ELEVATION > 3XULN WITH TOTAL BILIRUBIN > 2XULN WITHIN ONE DAY | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| CONCURRENT ALT OR AST ELEVATION > 3XULN WITH TOTAL BILIRUBIN > 2XULN WITHIN 30 DAYS | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Investigator-assessed ORR per International Working Group (IWG 2007) response criteria for malignant lymphoma is defined as the number of participants with a best overall documented response (BOR) of either a complete response (CR) or partial response (PR). Complete response: Disappearance of all evidence of disease. Partial response: Regression of measurable disease and no new sites. \>= 50% decrease in sum of the produce of the diameters of up to 6 largest dominant masses (index lesions); no increase in size of other nodes (non-index lesions). Progressive disease: Any new lesion or increase by \>=50% of previously involved sites from nadir.
| Percentage of participants | HL Naive BMS-986016 160mg + Nivolumab | DLBCL BMS-986016 160mg + Nivolumab | HL Post I/O BMS-986016 160mg + Nivolumab |
|---|---|---|---|
| Objective Response Rate (ORR) - Part D | 61.9 (38.4 to 81.9) | 6.7 (0.2 to 31.9) | 15.0 (3.2 to 37.9) |
Investigator-assessed DoR per International Working Group (IWG 2007)) response criteria for malignant lymphoma is defined as the time between the date of first documented response (complete response or partial response) to the date of the first objectively documented progression, or death due to any cause, whichever occurs first. Complete response: Disappearance of all evidence of disease. Partial response: Regression of measurable disease and no new sites. \>= 50% decrease in sum of the produce of the diameters of up to 6 largest dominant masses (index lesions); no increase in size of other nodes (non-index lesions). Progressive disease: Any new lesion or increase by \>=50% of previously involved sites from nadir.
| Months | HL Naive BMS-986016 160mg + Nivolumab | DLBCL BMS-986016 160mg + Nivolumab | HL Post I/O BMS-986016 160mg + Nivolumab |
|---|---|---|---|
| Duration of Response (DoR) - Part D | 14.16 (2.56 to NA) | NA (NA to NA) | 6.37 (1.84 to NA) |
BMS-986016 Maximum Observed Serum Concentration (Cmax). Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 = Re-challenge period
| ug/mL | BMS-986016 20mg | BMS-986016 80mg | BMS-986016 800mg | BMS-986016 240mg | BMS-986016 80mg + Nivolumab | BMS-986016 240mg + Nivolumab | BMS-986016 160mg + Nivolumab |
|---|---|---|---|---|---|---|---|
| Period 0, Cycle 1, Day 1 (P0C1D1) | 3.697 ± NA | 22.738 ± NA | 224.802 ± NA | 68.718 ± NA | 19.990 ± NA | 57.900 ± NA | 40.402 ± NA |
| P0C3D1 | 6.660 ± NA | 31.917 ± NA | 673.000 ± NA | 116.419 ± NA | 44.532 ± NA | 149.000 ± NA | 88.196 ± NA |
| P1C1D1 | — | — | — | — | — | 59.600 ± NA | 68.400 ± NA |
| P1C3D1 | — | — | — | — | — | 165.000 ± NA | 163.000 ± NA |
BMS-986016 Time of Maximum Observed Serum Concentration (Tmax). Period 0 = treatment period Period 1 = Re-challenge period
| Hours | BMS-986016 20mg | BMS-986016 80mg | BMS-986016 800mg | BMS-986016 240mg | BMS-986016 80mg + Nivolumab | BMS-986016 240mg + Nivolumab | BMS-986016 160mg + Nivolumab |
|---|---|---|---|---|---|---|---|
| Period 0, Cycle 1, Day 1 (P0C1D1) | 0.97 (0.97 to 0.97) | 1.300 (1.00 to 4.00) | 4.167 (1.00 to 24.00) | 1.825 (0.97 to 95.75) | 3.950 (1.00 to 5.00) | 0.97 (0.97 to 0.97) | 1.600 (0.97 to 24.07) |
| P0C3D1 | 0.984 (0.97 to 1.00) | 10.975 (1.37 to 20.58) | 168.22 (168.22 to 168.22) | 1.233 (0.97 to 23.87) | 1.017 (1.00 to 4.00) | 1.000 (1.00 to 1.00) | 3.467 (0.92 to 46.45) |
| P1C1D1 | — | — | — | — | — | 4.000 (4.00 to 4.00) | 1.750 (1.75 to 1.75) |
| P1C3D1 | — | — | — | — | — | 24.000 (24.00 to 24.00) | 0.900 (0.90 to 0.90) |
BMS-986016 Area under the concentration-time curve in one dosing interval (AUC(TAU)). Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 = Re-challenge period
| h*ug/mL | BMS-986016 20mg | BMS-986016 80mg | BMS-986016 800mg | BMS-986016 240mg | BMS-986016 80mg + Nivolumab | BMS-986016 240mg + Nivolumab | BMS-986016 160mg + Nivolumab |
|---|---|---|---|---|---|---|---|
| Period 0, Cycle 1, Day 1 (P0C1D1) | 401.438 ± NA | 2852.533 ± NA | 44296.525 ± NA | 9086.827 ± NA | 2908.011 ± NA | 9480.758 ± NA | 5327.954 ± NA |
| P0C3D1 | 712.408 ± NA | 4898.034 ± NA | 176405.369 ± NA | 18783.970 ± NA | 6166.165 ± NA | 34573.957 ± NA | 20464.075 ± NA |
| P1C1D1 | — | — | — | — | — | 11259.871 ± NA | 11433.253 ± NA |
| P1C3D1 | — | — | — | — | — | 38472.003 ± NA | 33919.259 ± NA |
BMS-986016 Concentration at the end of a dosing interval (Ctau). Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 = Re-challenge period
| h*ug/mL | BMS-986016 20mg | BMS-986016 80mg | BMS-986016 800mg | BMS-986016 240mg | BMS-986016 80mg + Nivolumab | BMS-986016 240mg + Nivolumab | BMS-986016 160mg + Nivolumab |
|---|---|---|---|---|---|---|---|
| Period 0, Cycle 1, Day 1 (P0C1D1) | 0.158 ± NA | 1.037 ± NA | 75.589 ± NA | 12.221 ± NA | 3.848 ± NA | 19.500 ± NA | 8.417 ± NA |
| P0C3D1 | 0.256 ± NA | 2.266 ± NA | 293.000 ± NA | 30.970 ± NA | 9.556 ± NA | 103.000 ± NA | 47.016 ± NA |
| P1C1D1 | — | — | — | — | — | 25.900 ± NA | 24.200 ± NA |
| P1C3D1 | — | — | — | — | — | 86.600 ± NA | 86.100 ± NA |
BMS-986016 effective elimination half-life that explains the degree of AUC accumulation observed (t 1/2eff AUC). Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 = Re-challenge period
| Hours | BMS-986016 20mg | BMS-986016 80mg | BMS-986016 800mg | BMS-986016 240mg | BMS-986016 80mg + Nivolumab | BMS-986016 240mg + Nivolumab | BMS-986016 160mg + Nivolumab |
|---|---|---|---|---|---|---|---|
| P0C3D1 | 240.671 ± 143.5338 | 742.843 ± NA | 547.986 ± NA | 428.698 ± 346.4046 | 548.741 ± 78.0213 | 720.317 ± NA | 674.755 ± 296.9473 |
| P1C3D1 | — | — | — | — | — | 638.597 ± NA | 524.637 ± NA |
BMS-986016 total body clearance (CL/T). Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 = Re-challenge period
| mL/h | BMS-986016 20mg | BMS-986016 80mg | BMS-986016 800mg | BMS-986016 240mg | BMS-986016 80mg + Nivolumab | BMS-986016 240mg + Nivolumab | BMS-986016 160mg + Nivolumab |
|---|---|---|---|---|---|---|---|
| P0C3D1 | 28.074 ± NA | 16.333 ± NA | 4.535 ± NA | 12.777 ± NA | 12.974 ± NA | 6.942 ± NA | 7.819 ± NA |
| P1C3D1 | — | — | — | — | — | 6.238 ± NA | 4.717 ± NA |
BMS-986016 cmax accumulation index (AI_Cmax). AI is calculated based on ratio of Cmax at steady state to Cmax after the first dose. Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 - Re-challenge period
| ug/mL | BMS-986016 20mg | BMS-986016 80mg | BMS-986016 800mg | BMS-986016 240mg | BMS-986016 80mg + Nivolumab | BMS-986016 240mg + Nivolumab | BMS-986016 160mg + Nivolumab |
|---|---|---|---|---|---|---|---|
| P0C3D1 | 1.981 ± NA | 1.701 ± NA | 2.009 ± NA | 1.734 ± NA | 2.369 ± NA | 2.573 ± NA | 2.139 ± NA |
| P1C3D1 | — | — | — | — | — | 2.768 ± NA | 2.383 ± NA |
BMS-986016 accumulation index (AI_AUC). AI is calculated based on ratio of AUC(TAU) at steady state to AUC(TAU) after the first dose. Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 - Re-challenge period
| Ratio | BMS-986016 20mg | BMS-986016 80mg | BMS-986016 800mg | BMS-986016 240mg | BMS-986016 80mg + Nivolumab | BMS-986016 240mg + Nivolumab | BMS-986016 160mg + Nivolumab |
|---|---|---|---|---|---|---|---|
| P0C3D1 | 1.577 ± NA | 1.850 ± NA | 2.894 ± NA | 2.186 ± NA | 2.017 ± NA | 3.647 ± NA | 3.268 ± NA |
| P1C3D1 | — | — | — | — | — | 3.417 ± NA | 2.967 ± NA |
BMS-986016 Ctau accumulation index (AI_Ctau). AI is calculated based on ratio of Ctau at steady state to Ctau after the first dose. Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 - Re-challenge period
| Ratio | BMS-986016 20mg | BMS-986016 80mg | BMS-986016 800mg | BMS-986016 240mg | BMS-986016 80mg + Nivolumab | BMS-986016 240mg + Nivolumab | BMS-986016 160mg + Nivolumab |
|---|---|---|---|---|---|---|---|
| P0C3D1 | 0.743 ± NA | 2.494 ± NA | 4.741 ± NA | 2.310 ± NA | 1.686 ± NA | 5.282 ± NA | 4.162 ± NA |
| P1C3D1 | — | — | — | — | — | 3.344 ± NA | 3.558 ± NA |
BMS-986016 average concentration over a dosing interval (\[AUC(TAU)/tau\] (Css,avg). Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 - Re-challenge period
| ug/mL | BMS-986016 20mg | BMS-986016 80mg | BMS-986016 800mg | BMS-986016 240mg | BMS-986016 80mg + Nivolumab | BMS-986016 240mg + Nivolumab | BMS-986016 160mg + Nivolumab |
|---|---|---|---|---|---|---|---|
| P0C3D1 | 2.117 ± NA | 14.738 ± NA | 526.269 ± NA | 57.790 ± NA | 18.345 ± NA | 103.805 ± NA | 61.385 ± NA |
| P1C3D1 | — | — | — | — | — | 120.595 ± NA | 109.013 ± NA |
BMS-986016 trough observed serum concentration (Ctrough). Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 - Re-challenge period
| ug/mL | BMS-986016 20mg | BMS-986016 80mg | BMS-986016 800mg | BMS-986016 240mg | BMS-986016 80mg + Nivolumab | BMS-986016 240mg + Nivolumab | BMS-986016 160mg + Nivolumab |
|---|---|---|---|---|---|---|---|
| P0C1D15 | 0.064 ± NA | 1.457 ± NA | 75.589 ± NA | 12.221 ± NA | 3.848 ± NA | 19.500 ± NA | 10.609 ± NA |
| P0C1D29 | 0.088 ± NA | 4.324 ± NA | 155.896 ± NA | 20.982 ± NA | 13.066 ± NA | 32.400 ± NA | 18.221 ± NA |
| P0C1D43 | — | — | — | — | 9.435 ± NA | 44.700 ± NA | 25.234 ± NA |
| P0C2D1 | 0.777 ± NA | 6.609 ± NA | 298.666 ± NA | 37.013 ± NA | 9.389 ± NA | 59.000 ± NA | 28.428 ± NA |
| P0C2D15 | — | — | — | — | 6.209 ± NA | 62.000 ± NA | 30.218 ± NA |
| P0C2D29 | — | — | 289.000 ± NA | — | 26.700 ± NA | 70.900 ± NA | 36.675 ± NA |
| P0C3D1 | 1.020 ± NA | 19.018 ± NA | 313.000 ± NA | 16.648 ± NA | 6.867 ± NA | 93.300 ± NA | 45.535 ± NA |
| P0C3D15 | 0.256 ± NA | 2.266 ± NA | 293.000 ± NA | 9.450 ± NA | 9.556 ± NA | 103.000 ± NA | 45.685 ± NA |
| P0C5D1 | 0.729 ± NA | 1.917 ± NA | — | 18.198 ± NA | 23.381 ± NA | 149.000 ± NA | 57.068 ± NA |
| P0C7D1 | — | 59.600 ± NA | — | 5.760 ± NA | 20.264 ± NA | 143.000 ± NA | 58.408 ± NA |
| P0C9D1 | — | 62.000 ± NA | — | 5.860 ± NA | 22.800 ± NA | 117.000 ± NA | 56.054 ± NA |
| P0C11D1 | — | 48.100 ± NA | — | 4.710 ± NA | 31.200 ± NA | 165.000 ± NA | 67.268 ± NA |
| P1C1D15 | — | — | — | — | — | 25.900 ± NA | 24.200 ± NA |
| P1C1D29 | — | — | — | — | — | 43.600 ± NA | 41.000 ± NA |
| P1C1D43 | — | — | — | — | — | 61.800 ± NA | 56.000 ± NA |
| P1C2D1 | — | — | — | — | — | 73.800 ± NA | 58.700 ± NA |
| P1C2D15 | — | — | — | — | — | 84.700 ± NA | 69.400 ± NA |
| P1C2D29 | — | — | — | — | — | 81.500 ± NA | 71.900 ± NA |
| P1C3D1 | — | — | — | — | — | 94.600 ± NA | 85.500 ± NA |
| P1C3D15 | — | — | — | — | — | 86.600 ± NA | 86.100 ± NA |
| P1C5D1 | — | — | — | — | — | 109.000 ± NA | 70.100 ± NA |
| P1C7D1 | — | — | — | — | — | 107.000 ± NA | 105.000 ± NA |
| P1C9D1 | — | — | — | — | — | 115.000 ± NA | 110.000 ± NA |
| P1C11D1 | — | — | — | — | — | — | 115.000 ± NA |
Number of participants with anti-BMS-986016 antibodies (ADA) with status as baseline ADA positive, ADA positive and ADA negative. Baseline ADA positive participant is defined as a participant with positive seroconversion detected in the last sample before initiation of treatment. ADA-positive participant is a participant with at least one ADA-positive sample relative to baseline after initiation of the treatment. ADA negative participant is defined as a participant with no ADA positive sample after the initiation of treatment.
| Participants | BMS-986016 20mg | BMS-986016 80mg | BMS-986016 800mg | BMS-986016 240mg | BMS-986016 80mg + Nivolumab | BMS-986016 240mg + Nivolumab | BMS-986016 160mg + Nivolumab |
|---|---|---|---|---|---|---|---|
| Baseline ADA Positive | 0 | 1 | 1 | 6 | 0 | 0 | 5 |
| ADA Positive | 0 | 0 | 0 | 7 | 3 | 0 | 4 |
| ADA Negative | 3 | 7 | 5 | 12 | 4 | 1 | 48 |
Number of participants with anti-Nivolumab antibodies (ADA) with status as baseline ADA positive, ADA positive and ADA negative. Baseline ADA positive participant is defined as a participant with positive seroconversion detected in the last sample before initiation of treatment. ADA-positive participant is a participant with at least one ADA-positive sample relative to baseline after initiation of the treatment. ADA negative participant is defined as a participant with no ADA positive sample after the initiation of treatment.
| Participants | BMS-986016 20mg | BMS-986016 80mg | BMS-986016 800mg | BMS-986016 240mg | BMS-986016 80mg + Nivolumab | BMS-986016 240mg + Nivolumab | BMS-986016 160mg + Nivolumab |
|---|---|---|---|---|---|---|---|
| Baseline ADA Positive | — | — | — | — | 0 | 0 | 0 |
| ADA Positive | — | — | — | — | 0 | 0 | 1 |
| ADA Negative | — | — | — | — | 4 | 1 | 45 |
Collected over Serious Adverse Events (SAEs) and Other (Not including Serious) Adverse Events (AEs) are collected from first dose to 135 days post last dose (Up to 52 months). Participants were assessed for All-cause mortality from their date of randomization to study completion (Up to approximately 95 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Mono Esc 20 Q2W | 2/3 (66.7%) | 1/3 (33.3%) | 3/3 (100%) |
| All Mono Esc 80 Q2W | 3/9 (33.3%) | 5/9 (55.6%) | 9/9 (100%) |
| All Mono Esc 240 Q2W | 0/9 (0%) | 1/9 (11.1%) | 8/9 (88.9%) |
| All Mono Esc 800 Q2W | 1/6 (16.7%) | 2/6 (33.3%) | 5/6 (83.3%) |
| CLL BMS-986016 240mg | 1/2 (50%) | 1/2 (50%) | 2/2 (100%) |
| DLBCL BMS-986016 240mg | 2/2 (100%) | 2/2 (100%) | 2/2 (100%) |
| iNHL BMS-986016 240mg | 0/4 (0%) | 2/4 (50%) | 4/4 (100%) |
| HL BMS-986016 240mg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| All Combo Esc 80/240 Q2W | 5/7 (71.4%) | 4/7 (57.1%) | 7/7 (100%) |
| All Combo Esc 160/240 Q2W | 2/4 (50%) | 2/4 (50%) | 4/4 (100%) |
| All Combo Esc 240/240 Q2W | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| HL Naive BMS-986016 160mg + Nivolumab | 1/21 (4.8%) | 6/21 (28.6%) | 20/21 (95.2%) |
| DLBCL BMS-986016 160mg + Nivolumab | 13/15 (86.7%) | 11/15 (73.3%) | 11/15 (73.3%) |
| HL Post I/O BMS-986016 160mg + Nivolumab | 3/20 (15%) | 9/20 (45%) | 20/20 (100%) |
| Event | All Mono Esc 20 Q2W | All Mono Esc 80 Q2W | All Mono Esc 240 Q2W | All Mono Esc 800 Q2W | CLL BMS-986016 240mg | DLBCL BMS-986016 240mg | iNHL BMS-986016 240mg | HL BMS-986016 240mg | All Combo Esc 80/240 Q2W | All Combo Esc 160/240 Q2W | All Combo Esc 240/240 Q2W | HL Naive BMS-986016 160mg + Nivolumab | DLBCL BMS-986016 160mg + Nivolumab | HL Post I/O BMS-986016 160mg + Nivolumab |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 3/9 | 0/9 | 1/6 | 0/2 | 2/2 | 0/4 | 0/3 | 2/7 | 0/4 | 0/1 | 1/21 | 9/15 | 0/20 |
| AnaemiaBlood and lymphatic system disorders | 0/3 | 0/9 | 0/9 | 0/6 | 0/2 | 1/2 | 0/4 | 0/3 | 0/7 | 0/4 | 0/1 | 0/21 | 0/15 | 0/20 |
| Blood thyroid stimulating hormone increasedInvestigations | 0/3 | 0/9 | 0/9 | 0/6 | 0/2 | 1/2 | 0/4 | 0/3 | 0/7 | 0/4 | 0/1 | 0/21 | 0/15 | 0/20 |
| DehydrationMetabolism and nutrition disorders | 0/3 | 0/9 | 0/9 | 0/6 | 0/2 | 1/2 | 1/4 | 0/3 | 0/7 | 0/4 | 0/1 | 0/21 | 0/15 | 0/20 |
| HeadacheNervous system disorders | 0/3 | 0/9 | 0/9 | 0/6 | 1/2 | 0/2 | 0/4 | 0/3 | 0/7 | 0/4 | 0/1 | 0/21 | 0/15 | 0/20 |
| Acute kidney injuryRenal and urinary disorders | 0/3 | 2/9 | 0/9 | 0/6 | 0/2 | 1/2 | 0/4 | 0/3 | 0/7 | 0/4 | 0/1 | 0/21 | 1/15 | 0/20 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/3 | 0/9 | 0/9 | 0/6 | 0/2 | 1/2 | 0/4 | 0/3 | 0/7 | 0/4 | 0/1 | 0/21 | 0/15 | 0/20 |
| AstheniaGeneral disorders | 1/3 | 0/9 | 0/9 | 0/6 | 0/2 | 0/2 | 0/4 | 0/3 | 0/7 | 0/4 | 0/1 | 0/21 | 0/15 | 0/20 |
| Non-cardiac chest painGeneral disorders | 0/3 | 0/9 | 0/9 | 0/6 | 0/2 | 0/2 | 0/4 | 1/3 | 0/7 | 0/4 | 0/1 | 0/21 | 0/15 | 0/20 |
| Periprosthetic fractureInjury, poisoning and procedural complications | 1/3 | 0/9 | 0/9 | 0/6 | 0/2 | 0/2 | 0/4 | 0/3 | 0/7 | 0/4 | 0/1 | 0/21 | 0/15 | 0/20 |
| Event | All Mono Esc 20 Q2W | All Mono Esc 80 Q2W | All Mono Esc 240 Q2W | All Mono Esc 800 Q2W | CLL BMS-986016 240mg | DLBCL BMS-986016 240mg | iNHL BMS-986016 240mg | HL BMS-986016 240mg | All Combo Esc 80/240 Q2W | All Combo Esc 160/240 Q2W | All Combo Esc 240/240 Q2W | HL Naive BMS-986016 160mg + Nivolumab | DLBCL BMS-986016 160mg + Nivolumab | HL Post I/O BMS-986016 160mg + Nivolumab |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lymph node painBlood and lymphatic system disorders | 0/3 | 0/9 | 0/9 | 1/6 | 2/2 | 0/2 | 0/4 | 0/3 | 0/7 | 0/4 | 0/1 | 0/21 | 0/15 | 0/20 |
| DiarrhoeaGastrointestinal disorders | 1/3 | 3/9 | 0/9 | 1/6 | 0/2 | 0/2 | 2/4 | 1/3 | 3/7 | 0/4 | 1/1 | 5/21 | 2/15 | 3/20 |
| Gingival painGastrointestinal disorders | 0/3 | 0/9 | 0/9 | 0/6 | 0/2 | 0/2 | 0/4 | 0/3 | 0/7 | 0/4 | 1/1 | 0/21 | 0/15 | 0/20 |
| StomatitisGastrointestinal disorders | 0/3 | 0/9 | 0/9 | 0/6 | 1/2 | 0/2 | 0/4 | 0/3 | 1/7 | 0/4 | 1/1 | 1/21 | 0/15 | 0/20 |
| Mucosal inflammationGeneral disorders | 0/3 | 1/9 | 0/9 | 0/6 | 0/2 | 0/2 | 0/4 | 0/3 | 1/7 | 0/4 | 1/1 | 0/21 | 0/15 | 1/20 |
| PainGeneral disorders | 0/3 | 1/9 | 0/9 | 0/6 | 0/2 | 0/2 | 0/4 | 0/3 | 1/7 | 0/4 | 1/1 | 0/21 | 0/15 | 0/20 |
| Fungal infectionInfections and infestations | 0/3 | 0/9 | 0/9 | 0/6 | 0/2 | 0/2 | 0/4 | 0/3 | 0/7 | 0/4 | 1/1 | 0/21 | 0/15 | 0/20 |
| Herpes zosterInfections and infestations | 1/3 | 0/9 | 0/9 | 0/6 | 0/2 | 0/2 | 0/4 | 0/3 | 0/7 | 0/4 | 1/1 | 1/21 | 0/15 | 0/20 |
| Respiratory syncytial virus infectionInfections and infestations | 0/3 | 0/9 | 0/9 | 0/6 | 0/2 | 0/2 | 0/4 | 0/3 | 0/7 | 0/4 | 1/1 | 0/21 | 0/15 | 0/20 |
| Upper respiratory tract infectionInfections and infestations | 1/3 | 2/9 | 2/9 | 0/6 | 1/2 | 0/2 | 0/4 | 1/3 | 2/7 | 2/4 | 1/1 | 6/21 | 1/15 | 4/20 |
| Age, Categorical(Participants) | BMS-986016 20mg | BMS-986016 800mg | BMS-986016 80mg | BMS-986016 240mg | BMS-986016 80mg + Nivolumab | BMS-986016 240mg + Nivolumab | BMS-986016 160mg + Nivolumab | Total |
|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 3 | 5 | 12 | 3 | 1 | 46 | 72 |
| >=65 years | 1 | 6 | 1 | 8 | 4 | 0 | 14 | 34 |
| Sex: Female, Male(Participants) | BMS-986016 20mg | BMS-986016 800mg | BMS-986016 80mg | BMS-986016 240mg | BMS-986016 80mg + Nivolumab | BMS-986016 240mg + Nivolumab | BMS-986016 160mg + Nivolumab | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 0 | 5 | 1 | 6 | 4 | 0 | 22 | 38 |
| Male | 3 | 4 | 5 | 14 | 3 | 1 | 38 | 68 |
| Ethnicity (NIH/OMB)(Participants) | BMS-986016 20mg | BMS-986016 800mg | BMS-986016 80mg | BMS-986016 240mg | BMS-986016 80mg + Nivolumab | BMS-986016 240mg + Nivolumab | BMS-986016 160mg + Nivolumab | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 1 | 1 | 0 | 0 | 2 | 4 |
| Not Hispanic or Latino | 3 | 9 | 5 | 19 | 7 | 1 | 58 | 102 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | BMS-986016 20mg | BMS-986016 800mg | BMS-986016 80mg | BMS-986016 240mg | BMS-986016 80mg + Nivolumab | BMS-986016 240mg + Nivolumab | BMS-986016 160mg + Nivolumab | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Black or African American | 1 | 1 | 1 | 2 | 0 | 0 | 4 | 9 |
| White | 1 | 8 | 5 | 16 | 7 | 1 | 45 | 83 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 2 | 0 | 0 | 5 | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2014 to primary completion in Feb 2022, 95 months.
Results were first posted in Mar 2023, 1 year 1 month after primary completion.
Of 64 phase 1/2 interventional studies under Hematologic Neoplasms, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 127. This study's 95 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Relatlimab